Pharmacometabolomics identifies dodecanamide and leukotriene B4 dimethylamide as a predictor of chemosensitivity for patients with acute myeloid leukemia treated with cytarabine and anthracycline.
about
Pharmacometabolomics identifies dodecanamide and leukotriene B4 dimethylamide as a predictor of chemosensitivity for patients with acute myeloid leukemia treated with cytarabine and anthracycline.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Pharmacometabolomics identifie ...... cytarabine and anthracycline.
@en
Pharmacometabolomics identifie ...... cytarabine and anthracycline.
@nl
type
label
Pharmacometabolomics identifie ...... cytarabine and anthracycline.
@en
Pharmacometabolomics identifie ...... cytarabine and anthracycline.
@nl
prefLabel
Pharmacometabolomics identifie ...... cytarabine and anthracycline.
@en
Pharmacometabolomics identifie ...... cytarabine and anthracycline.
@nl
P2093
P2860
P356
P1433
P1476
Pharmacometabolomics identifie ...... cytarabine and anthracycline.
@en
P2093
Bingbing Zhao
Guangguo Tan
Hong Xiong
Yanqing Li
Yanyu Wang
Zhilan Zou
P2860
P304
88697-88707
P356
10.18632/ONCOTARGET.20733
P407
P577
2017-09-08T00:00:00Z